Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create best-in-class new drugs in the areas of cancer, infection and autoimmune disease. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Find out more

Latest News

Cancer research collaboration with Horizon Discovery Group plc
3 September 2015

Redx is pleased to announce a cancer research collaboration with Horizon Discovery Group plc, ("Horizon"), the international life science group.

The collaboration will focus on Redx's existing pan-RAF inhibitor program, which is focused on colorectal cancer, the fourth most common cancer and the second most common cause of cancer death in the UK.

Redx's pan-RAF inhibitor program has identified next generation novel small molecule inhibitors of RAF kinases as potential treatments for colorectal and other potential cancers. These next generation pan-Raf inhibitors have been designed to overcome resistance mechanisms seen with first generation Raf inhibitors in colorectal cancer.

Read more

We're Hiring

As a fast-growing dynamic business we are continually looking for talented people to join our team.

Work for us

Investor News

22 June 2015

Announcing our maiden unaudited results for the six months ended 31 March 2015.

Investor Relations

Our Subsidiary Companies

Discovering and developing new therapeutics in the area of infectious disease generating a pipeline of novel antibacterial & antiviral drugs.

View details

Modulating the immune system with novel small molecules to treat a range of diseases with high unmet medical need.

View details

Applying our proprietary method to deliver multiple development candidates across a range of mechanistic approaches in cancer treatment.

View details